Mitral valve prolapse

Icahn School of Medicine at Mount Sinai Awarded $10.2 Million NIH Grant to Explore the Early Signs of Arrhythmic Mitral Valve Prolapse

Retrieved on: 
Tuesday, September 26, 2023
Pi, American Heart Association, National Heart, Lung, and Blood Institute, Pathology, Arrhythmia, Doctor of Philosophy, Associate, Bangladesh Technical Education Board, Interventional radiology, Magnetic resonance imaging, Mitral regurgitation, Patient, Risk, Heart, Disease, Inflammation, Sudden death, Heart failure, Principal investigator, Diagnosis, Research, Prolapse, Cardiac electrophysiology, Mitral valve, Biomedical engineering, Death, Cardiac arrest, Mitral valve prolapse, Echocardiography, Stroke, Mount Sinai, Assistant, Fibrosis, Cardiology, Icahn School of Medicine at Mount Sinai, Mount Sinai Health System, Blood, PET, Shahid Gangalal National Heart Centre, Lung, MRI, Scientific Computing and Imaging Institute, Recurrence, Pharmaceutical industry, Medical device, Medical imaging, Radiology, MD, Medicine

NEW YORK, Sept. 26, 2023 /PRNewswire-PRWeb/ -- Researchers at the Icahn School of Medicine at Mount Sinai have been awarded a $10.2 million grant from the National Heart, Lung and Blood Institute of the National Institutes of Health to investigate risk factors for malignant arrhythmias in mitral valve prolapse. This work aims to develop a better understanding of the condition and novel solutions to improve patient outcomes.

Key Points: 
  • The grant is a collaboration between four Icahn Mount Sinai specialties: Cardiac Electrophysiology, Cardiology, Cardiovascular Surgery, and the BioMedical Engineering and Imaging Institute (BMEII).
  • The grant is a collaboration between four Icahn Mount Sinai specialties: Cardiac Electrophysiology, Cardiology, Cardiovascular Surgery, and the BioMedical Engineering and Imaging Institute (BMEII).
  • In the United States, it is estimated that between 7 and 9 million people have mitral valve prolapse, the most common form of valve disease.
  • Mitral valve prolapse occurs when two flaps within the mitral valve don't close smoothly or evenly, but instead bulge (prolapse) upward into the left atrium when the heart contracts.

Global Autosomal Dominant Polycystic Kidney Disease Epidemiology Forecast Report to 2032 - ResearchAndMarkets.com

Retrieved on: 
Friday, October 7, 2022
Genetics, Pharmaceutical, Health, Arachnoid, Epidemiology, Cyst, Hypertension, Colin L. Masters, Doctor of Philosophy, ERM, PKD2, Growth, Population, Diagnosis, Mitral valve prolapse, Kidney failure, Patient, Urinary tract infection, Degenerative disease, Renal cysts and diabetes syndrome, Kidney, Diverticular disease, Polycystic kidney disease, Hernia, Stabat Mater, Hematuria, Adult, Liver, United Kingdom, Fibrosis, PKD1, Master's degree, Intracranial aneurysm, Autosome, Left ventricular hypertrophy, Chronic kidney disease, Pancreas, Autosomal dominant polycystic kidney disease, PKD, Vaccine, Pharmaceutical industry, Lithium, Medical device, Health insurance, Management

The "Autosomal Dominant Polycystic Kidney Disease - Epidemiology Forecast - 2032" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Autosomal Dominant Polycystic Kidney Disease - Epidemiology Forecast - 2032" report has been added to ResearchAndMarkets.com's offering.
  • This report delivers an in-depth understanding of Autosomal Dominant Polycystic Kidney Disease, historical and forecasted epidemiology as well as Autosomal Dominant Polycystic Kidney Disease trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.
  • The diagnosed prevalent cases of Autosomal Dominant Polycystic Kidney Disease are likely to change by 2032 in the forecast period 2022-2032.
  • The report provides the segmentation of the disease epidemiology for the 7MM, a total number of total Diagnosed Prevalent Cases of Autosomal Dominant Polycystic Kidney Disease, Age-specific cases of Autosomal Dominant Polycystic Kidney Disease, and Mutation-specific cases of Autosomal Dominant Polycystic Kidney Disease.

Virtual Care Up, Stethoscope Tests Down: Experts Concerned About Risk of Undiagnosed Heart Valve Disease

Retrieved on: 
Wednesday, July 7, 2021
Medicine, Circulatory system, Clinical medicine, Valvular heart disease, Heart murmur, Turbulence, Stethoscope, Heart, Mitral valve prolapse, Cardiac myxoma

61% of those surveyed say they have not had a stethoscope check, a key diagnostic tool for uncovering heart valve disease, for more than one year.

Key Points: 
  • 61% of those surveyed say they have not had a stethoscope check, a key diagnostic tool for uncovering heart valve disease, for more than one year.
  • We've got to help Canadians balance the benefits and ease of virtual care with also making sure to have their heart listened to.
  • This is especially important when you factor in population health studies which show the prevalence of heart valve disease and the fact that many people with heart valve disease do not have symptoms.
  • Detection of heart valve disease involves identifying a heart murmur using a stethoscope followed by an echocardiogram to confirm the diagnosis.

Health Disparities Take Centerstage During Fifth Annual Heart Valve Disease Awareness Day

Retrieved on: 
Tuesday, February 23, 2021
Valvular heart disease, Anatomy, Heart, Circulatory system, Mitral valve, Mitral insufficiency, Heart valve, National Heart Valve Disease Awareness Day, Mitral valve prolapse

WASHINGTON, Feb. 23, 2021 /PRNewswire/ --On February 22, the Association of Black Cardiologists (ABC) joined more than 90 national organizations and thousands of patient advocates in recognizing the fifth annual Heart Valve Disease Awareness Day ("Valve Disease Day").

Key Points: 
  • WASHINGTON, Feb. 23, 2021 /PRNewswire/ --On February 22, the Association of Black Cardiologists (ABC) joined more than 90 national organizations and thousands of patient advocates in recognizing the fifth annual Heart Valve Disease Awareness Day ("Valve Disease Day").
  • Valve Disease Day offers an opportunity for the ABCto highlight risk factors, diagnosis, treatment and access to treatment as well as the disproportionate impact heart valve disease (HVD) has on communities of color in this country.
  • Millions of Americans have heart valve disease and every year, an estimated 25,000 people in the U.S. die from the disease.
  • Blacks also tend to be diagnosed with mitral valve disease, a common type of HVD, 15 years younger on average than Whites .

Foldax Receives FDA Approval to Initiate Clinical Study of Biopolymer Mitral Heart Valve

Retrieved on: 
Monday, December 14, 2020
Health, FDA, Medical devices, Surgery, Clinical trials, Cardiology, Biotechnology, Anatomy, Cardiac surgery, Heart, Valvular heart disease, Medicine, Heart valves, Mitral valve, Heart valve, MitraClip, Mitral valve prolapse

Foldax , Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted IDE approval for the company to initiate a U.S. clinical study of its Tria biopolymer mitral surgical heart valve.

Key Points: 
  • Foldax , Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted IDE approval for the company to initiate a U.S. clinical study of its Tria biopolymer mitral surgical heart valve.
  • The company anticipates the first use of its mitral valve in a human will take place in the coming weeks.
  • The mitral valve is the second of three Tria biopolymer heart valve products in the Foldax portfolio, and addresses a large unmet clinical need based on the prevalence of rheumatic fever worldwide.
  • The first of the companys products an aortic surgical heart valve is currently enrolling a U.S. clinical study as a result of FDA approval of an expanded study last October.

CardioMech Expands Mitral Leadership Team

Retrieved on: 
Monday, March 18, 2019
Health, Biotechnology, Cardiology, Medical devices, Medical specialties, Medicine, Circulatory system, Valvular heart disease, Cardiac surgery, Mitral valve, Regurgitation, Mitral insufficiency, Heart valve, Prolapse, Mitral valve prolapse

CardioMech AS , a privately held company developing a transcatheter mitral valve repair technology, today announced it has expanded its leadership team with the election of two new board directors Kathleen Tune of Fourth Element Capital , and Frederik Groenewegen of 415 CAPITAL , a board advisor, Vic Bertrand and appointed Daniele Salamone as Vice President of Finance.

Key Points: 
  • CardioMech AS , a privately held company developing a transcatheter mitral valve repair technology, today announced it has expanded its leadership team with the election of two new board directors Kathleen Tune of Fourth Element Capital , and Frederik Groenewegen of 415 CAPITAL , a board advisor, Vic Bertrand and appointed Daniele Salamone as Vice President of Finance.
  • The CardioMech device is a highly differentiated technology designed to significantly improve the standard of care for patients suffering from severe, symptomatic degenerative mitral regurgitation due to prolapse or flail.
  • I am extremely pleased to announce this expansion of CardioMechs mitral leadership team with the addition of four experienced medical technology professionals, said Rick Nehm , President and CEO of CardioMech.

FDA approves new indication for valve repair device to treat certain heart failure patients with mitral regurgitation

Retrieved on: 
Thursday, March 14, 2019
Heart diseases, Circulatory system, Valvular heart disease, Cardiovascular system, MitraClip, Mitral insufficiency, Cardiac resynchronization therapy, Mitral valve, Regurgitation, Atrial fibrillation, Heart valve, Mitral valve prolapse

When first approved in 2013 , the MitraClip Clip Delivery System (MitraClip) was indicated to reduce mitral regurgitation in certain patients whose significant mitral regurgitation and heart failure symptoms result from abnormalities of the mitral valve (commonly known as primary or degenerative mitral regurgitation) and whose risks for mitral valve surgery are prohibitive.

Key Points: 
  • When first approved in 2013 , the MitraClip Clip Delivery System (MitraClip) was indicated to reduce mitral regurgitation in certain patients whose significant mitral regurgitation and heart failure symptoms result from abnormalities of the mitral valve (commonly known as primary or degenerative mitral regurgitation) and whose risks for mitral valve surgery are prohibitive.
  • The new indication, approved today, is for treatment of patients with normal mitral valves who develop heart failure symptoms and moderate-to-severe or severe mitral regurgitation because of diminished left heart function (commonly known as secondary or functional mitral regurgitation) despite being treated with optimal medical therapy.Optimal medical therapy includes combinations of different heart failure medications along with, in certain patients, cardiac resynchronization therapy and implantation of cardioverter defibrillators.
  • A small percentage of these patients also have moderate-to-severe or severe secondary mitral regurgitation, increasing the risks and complicating the treatment of their heart failure.
  • Potential adverse events from the device and implant procedure include death, stroke, major bleeding, and erratic heart beat (atrial fibrillation).

Transcatheter Mitral Valve Repair Device Market, Europe, Units Sold, Average Selling Prices, Forecasts, 2018-2024, MedCore

Retrieved on: 
Wednesday, October 10, 2018
Heart, Circulatory system, Heart valves, Medicine, Valvular heart disease, Cardiac surgery, Cardiology, Aortic valve, Heart murmurs, Mitral valve prolapse, Mitral valve, Regurgitation

Growth will be driven by the large potential patient population, improved diagnostic capabilities, new product launches, positive clinical results and favorable reimbursement conditions.

Key Points: 
  • Growth will be driven by the large potential patient population, improved diagnostic capabilities, new product launches, positive clinical results and favorable reimbursement conditions.
  • It is worth noting that while reimbursement for TMVR limits growth in certain countries, the overall reimbursement landscape is favorable in Europe.
  • Of the four valves in the human heart (mitral valve, tricuspid valve, aortic valve and pulmonary valve), the mitral valve is most prone to regurgitation.
  • Mitral regurgitation (MR) can either be caused by a congenital defect or myxomatous degeneration of the valve.

Landmark Study Shows Treatment with Abbott's MitraClip® is Superior to Medical Therapy for Advanced Heart Failure Patients with Significant Secondary Mitral Regurgitation

Retrieved on: 
Sunday, September 23, 2018
Valvular heart disease, Circulatory system, Cardiology, Medicine, MitraClip, Mitral insufficiency, Regurgitation, Heart failure, Mitral valve, Clinical endpoint, Mitral valve prolapse

The landmark COAPT study met both the primary safetyand efficacy endpoints andall secondary endpoints, and showed treatment with MitraClip plus medical therapy was superior to medical therapy alone in reducing rates of heart failure hospitalizations and improving survival at two years.

Key Points: 
  • The landmark COAPT study met both the primary safetyand efficacy endpoints andall secondary endpoints, and showed treatment with MitraClip plus medical therapy was superior to medical therapy alone in reducing rates of heart failure hospitalizations and improving survival at two years.
  • This therapeutic mitral valve intervention is the first and only to demonstrate positive outcomes in a clinical trial for ailing heart failure patients with clinically significant secondary mitral regurgitation.
  • In the COAPT (Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients with Functional Mitral Regurgitation) study, 614 symptomatic heart failure patients with moderate-to-severe or severe secondary MR were randomized to receive treatment with MitraClip plus guideline-directed medical therapy or guideline-directed medical therapy alone at 78 sites in the U.S. and Canada.
  • MitraClip is currently under investigation to treat clinically significant secondary mitral regurgitation in the U.S. and not approved by the FDA for secondary mitral regurgitation.

4C Medical's AltaValve First In Human Experience to be Presented at TCT 2018

Retrieved on: 
Thursday, September 13, 2018
Circulatory system, Valvular heart disease, Medicine, Heart, Cardiac surgery, Cardiology, Mitral valve, Regurgitation, Mitral insufficiency, Heart valve, Mitral valve annuloplasty, Mitral valve prolapse

In contrast with other TMVRdevices, the AltaValve is the first mitral regurgitation (MR) treatment device that is placed in the left atrium, thus preserving the left ventricle.

Key Points: 
  • In contrast with other TMVRdevices, the AltaValve is the first mitral regurgitation (MR) treatment device that is placed in the left atrium, thus preserving the left ventricle.
  • Furthermore, due to supra-annular positioning of the valve, AltaValve avoids issues related to the complexity and dynamics of the mitral annulus, making it suitable for patients independent of their MR mechanism.
  • The AltaValve is a self-expanding device that may be inserted into the left atrium using either a transseptal or a transapical delivery system.
  • 4C Medical is a medical device company developing minimally invasive therapies for structural heart disease.